By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Development of endocrine resistance remains a challenge in the…
By Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center Data from two phase III trials showed that adding immune…
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam…
Palbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival By Dr.…
By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors…
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the…
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Attainment of pathological complete response (pCR) of breast cancer is…
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone…
By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School "Overall, a major shift in the way we treat breast…